Please enter exact key words
Our Current Pipelines
Program Indication Discovery Preclinical Phase1 Phase2 Phase3
Pro-001 Ovarian Cancer
Pro-002 Breast Cancer
Pro-001 Acute Myeloid Leukemia (AML)
PTG-01 Acute Lymphoblastic Leukemia (ALL)
CHR-106-CAR-T * Ovarian Cancer
RP215-CAR-T * Ovarian Cancer
Anti-Scg3 Therapeutic Antibody Diabetic Retinopathy(DR)

As a thriving pharmaceutical company, Protheragen Inc. ("Protheragen") focuses on acquiring, developing and commercializing novel pharmaceutical and biotechnology products for both therapeutic purposes and diagnostic applications. Guided by our advanced business strategy – the “VIC R&D model”: V (risk investment), I (IP right) and C (CRO), we are dedicated to making drug discovery and development activities the most effective via a collection of efforts and advantages from all agencies. Our streamlined management structure and rich trading experience allow us to seize opportunities that may elapse in a second and enable us to select from a series of options the best corporate or financial structure so as to successfully develop each product candidate. We believe drug development surely will be accelerated by combining Protheragen's skills and expertise.

Protheragen Inc.

2200 Smithtown Avenue, Room 1, Ronkonkoma,
NY 11779-7329, USA
Phone: 1-516-765-9461    Fax: 1-516-927-0118

Opening Hours

Monday — Sunday: 9am — 6pm